



Bibliography

Chromogranin A (CgA) in Prostate Cancer

September 2020

Recommended reading

SUBJECT	CgA Number
Studies	001, 002 , 003 , 004 , 005, 006, 007, 008, 009, 010, 011, 012 , 013, 014, 015, 016 , 017 , 018, 019, 020, 021 , 022 , 023, 024, 025, 026, 027, 028, 029, 030 , 031, 032 , 033, 034 , 035, 036 , 037, 038 , 039, 040, 041, 042, 043, 044, 045, 046, 047, 048, 049 , 051 , 052, 053 , 054, 055, 056, 057, 058 , 059, 060* , 061* , 062*, 064 , 065* , 066 , 068 , 070*
Reviews / Meta-Analysis	050 , 063 , 067 , 069

red marked = new

bold = particularly relevant

* = CgA on B·R·A·H·M·S™ KRYPTOR™

(Multiple categorization possible)

Summary of literature

See literature review and study overview with the title “Chromogranin A for therapy monitoring of patients with prostate cancer” (Study Review CgA in PC 107735.2 EN).

This document is a summary and review of some of the key studies on the use of CgA in prostate cancer.

Complete list of Literature

CGA 070 Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer

Szarvas T, Csizmarik A, Fazekas T, Huttli A, Nyirady P, Hadaschik B, Grunwald V, Pullen L, Juranyi Z, Kocsis Z, Shariat SF, Sevcenco S, Maj-Hes A and Kramer G
BJU Int 2020;Apr 20: (Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/32314509>

Method used: CgA on B·R·A·H·M·S™ KRYPTOR™

CGA 069 Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer

Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F and Cheng L
Cells 2020;9 (5),Apr 25: Open Access (Reviews/ Meta-Analysis)

<https://www.ncbi.nlm.nih.gov/pubmed/32344931>

CGA 068 Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: a Single-Center Retrospective Study

Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns J, Ross TL and Bengel FM
J Nucl Med 2020;Mar 13: (Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/32169910>

CGA 067 Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?

Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, Briganti A, de Visschere P, Mathieu R, Valerio M, van den Bergh R, Ost P, Mirvald C, Tilki D, Ploussard G, Surcel C and Party E-YPCW
Cancer Treat Rev 2019;75 May: 20-26. (Reviews/ Meta-Analysis)

<https://www.ncbi.nlm.nih.gov/pubmed/30875581>

CGA 066 Response Prediction of (177)Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase

Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Rohrich M, Kopka K, Hohenfellner M, Giesel FL, Haberkorn U and Kratochwil C

J Nucl Med 2020;61 (5),May: 689-695.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/31653712>

CGA 065 Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer

Giridhar KV, Sanhueza C, Hillman DW, Alkhateeb H, Carlson R, Tan W, Costello BA, Quevedo F, Pagliaro L and Kohli M
Prostate Cancer Prostatic Dis 2018;21 (3),Sep: 431-437.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/29858590>

Method used: CgA on B·R·A·H·M·S™ KRYPTOR™

CGA 064 Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G and De Giorgi U

Sci Rep 2018;8 (1),Oct 18: 15442.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/30337589>

CGA 063 [Neuroendocrine prostate cancer]

Tritschler S, Erdelkamp R, Stief C and Hentrich M

Urologe A 2017;56 (11),Nov: 1475-1484.(Reviews/ Meta-Analysis)

<https://www.ncbi.nlm.nih.gov/pubmed/29063171>

CGA 062 Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival

Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szucs M, Nyirady P, Romics I, Rubben H and Szarvas T
Pathol Oncol Res 2017;23 (3),Jul: 643-650.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/28012116>

Method used: CgA on B·R·A·H·M·S™ KRYPTOR™

CGA 061 Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel

J VONH, Schwartz M, Werner T, Fuxius S, Muller M, Frangenheim T, Bolenz C, Weiss C and Heinrich E
Anticancer Res 2017;37 (9),Sep: 5117-5124.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/28870943>

Method used: CgA on B·R·A·H·M·S™ KRYPTOR™

CGA 060 Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy

Heck MM, Thaler MA, Schmid SC, Seitz AK, Tauber R, Kubler H, Maurer T, Thalgott M, Hatzichristodoulou G, Hoppner M, Nawroth R, Luppia PB, Gschwend JE and Retz M
BJU Int 2017;119 (1),Jan: 30-37.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/27037533>

Method used: CgA on B·R·A·H·M·S™ KRYPTOR™

CGA 059 Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer

Fan L, Wang Y, Chi C, Pan J, Xun S, Xin Z, Hu J, Zhou L, Dong B and Xue W
BJU Int 2017;120 (2),Aug: 226-232.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/28107595>

CGA 058 Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer

Dong B, Fan L, Wang Y, Chi C, Ma X, Wang R, Cai W, Shao X, Pan J, Zhu Y, Shangguan X, Xin Z, Hu J, Xie S, Kang X, Zhou L and Xue W
Prostate 2017;77 (13),May: 1373-1380.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/28804908>

CGA 057 Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naive castration-resistant prostate cancer

von Hardenberg J, Schwartz M, Werner T, Fuxius S, Muller M, Bolenz C, Weiss C and Heinrich E
Prostate 2016;76 (7),May: 613-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/26779767>

CGA 056 The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Mahammedi H, Planchat E, Pouget M, Durando X, Cure H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, Gadea E, Abrial C, Thivat E, Chollet P and Eymard JC
Oncology 2016;90 (2),69-78.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/26771576>

CGA 055 Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer

Gong Y, Chippada-Venkata UD, Galsky MD, Huang J and Oh WK
Prostate 2015;75 (6),May: 616-27.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/25560638>

CGA 054 Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of Prostate Cancer

Capoun O, Soukup V, Kalousova M, Sobotka R, Pesl M, Zima T and Hanus T
Urol Int 2015;95 (4),429-35.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/26159681>

CGA 053 Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy

Hirano D, Hasegawa R, Satoh K, Mochida J, Yamanaka Y, Hirakata H, Yamaguchi K, Sugimoto S, Kawata N and Takahashi S
Scand J Urol 2014;48 (5),Oct: 436-44.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/24730473>

CGA 052 Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature

D'Angelillo RM, Greco C, Fiore M, Ippolito E, Eolo Trodella L, Iurato A, Molfese E, Ramella S and Trodella L

Tumori 2014;100 (3),May-Jun: 249-53.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/25076233>

CGA 051 Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D and De Giorgi U
Prostate 2014;74 (16),Dec: 1691-6.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/25262981>

CGA 050 Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies

Conteduca V, Aieta M, Amadori D and De Giorgi U
Crit Rev Oncol Hematol 2014;92 (1),Oct: 11-24.(Reviews/ Meta-Analysis)
<https://www.ncbi.nlm.nih.gov/pubmed/24952997>

CGA 049 Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D and De Giorgi U
Endocr Relat Cancer 2014;21 (3),Jun: 487-93.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/24741024>

CGA 048 Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery

Sciarra A, Cattarino S, Gentilucci A, Alfarone A, Innocenzi M, Gentile V and Salciccia S
Urol Oncol 2013;31 (5),Jul: 607-14.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/21665494>

CGA 047 Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers

Tarjan M, Chen HH, Tot T, Wu W, Lenngren A, Dean PB and Tabar L
Scand J Urol Nephrol 2012;46 (4),Aug: 258-66.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/22519924>

CGA 046 Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt

Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F, Tringali V, Detti S and de Cobelli O
Clin Genitourin Cancer 2012;10 (3),Sep: 164-73.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/22401754>

CGA 045 The prognostic role of preoperative chromogranin A expression in prostate cancer after radical prostatectomy

Masieri L, Lanciotti M, Gontero P, Marchioro G, Mantella A, Zaramella S, Minervini A, Lapini A, Carini M and Serni S
Arch Ital Urol Androl 2012;84 (1),Mar: 17-21.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/22649955>

CGA 044 Correlation between age and Chromogranin A determination in prostate diseases

Mearini L, Zucchi A, Scarponi E, Nunzi E, Aglietti MC, Bini V and Porena M
Cancer Biomark 2011;10 (3-4),117-23.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/22674297>

CGA 043 Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP and Culine S
Ann Oncol 2011;22 (11),Nov: 2476-81.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/21436186>

CGA 042 Gastrin-releasing peptide: predictor of castration-resistant prostate cancer?

Heinrich E, Probst K, Michel MS and Trojan L
Prostate 2011;71 (6),May: 642-8.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/20945407>

CGA 041 Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy

Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, Mavuduru RS and Prasad R
Cancer Biomark 2010;8 (2),81-7.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/21896995>

CGA 040 Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer

Reis LO, Vieira LF, Zani EL, Denardi F, de Oliveira LC and Ferreira U

J Investig Med 2010;58 (8),Dec: 957-60.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/20818262>

CGA 039 Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma

Appetecchia M, Mecule A, Pasimeni G, Iannucci CV, De Carli P, Baldelli R, Barnabei A, Cigliana G, Sperduti I and Gallucci M

J Exp Clin Cancer Res 2010;29 Dec 17: 166.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/21162758>

CGA 038 The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state

Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E and Touloupidis S

Hell J Nucl Med 2009;12 (3),Sep-Dec: 234-7.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/19936334>

CGA 037 Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendocrine differentiation and aggressive prostate cancer

Tarle M, Spajic B, Kraljic I and Kusic Z

Anticancer Res 2009;29 (5),May: 1797-801.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/19443407>

CGA 036 Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma

Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A and Gentile V

Urol Int 2009;82 (2),147-51.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/19321999>

CGA 035 Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia

Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V and Di Silverio F

Urol Int 2008;80 (1),68-73.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/18204237>

CGA 034 Implications of circulating chromogranin A in prostate cancer

Hirano D, Minei S, Sugimoto S, Yamaguchi K, Yoshikawa T, Hachiya T, Kawata N, Yoshida T and Takahashi S

Scand J Urol Nephrol 2007;41 (4),297-301.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/17763220>

CGA 033 Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers

Culine S, El Demery M, Lamy PJ, Iborra F, Avances C and Pinguet F

J Urol 2007;178 (3 Pt 1),Sep: 844-8; discussion 848.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/17631339>

CGA 032 Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease

Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM and Dogliotti L

J Urol 2007;178 (3 Pt 1),Sep: 838-43; quiz 1129.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/17631319>

CGA 031 The chromogranin-A (CgA) in prostate cancer

Ranno S, Motta M, Rampello E, Risino C, Bennati E and Malaguarnera M

Arch Gerontol Geriatr 2006;43 (1),Jul-Aug: 117-26.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/16280180>

CGA 030 Circulating chromogranin a and hormone refractory prostate cancer chemotherapy

Cabrespine A, Guy L, Gachon F, Cure H, Chollet P and Bay JO

J Urol 2006;175 (4),Apr: 1347-52.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/16515996>

CGA 029 Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ and Kantoff PW
Urology 2005;66 (2),Aug: 386-91.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/16098367>

CGA 028 Chromogranin A expression in familial versus sporadic prostate cancer

Sciarra A, Monti S, Gentile V, Salciccia S, Autran Gomez AM, Pannunzi LP and Di Silverio F
Urology 2005;66 (5),Nov: 1010-4.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/16286114>

CGA 027 Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients

Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K and Ichikawa T
Eur Urol 2005;48 (2),Aug: 224-9; discussion 229-30.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/16005374>

CGA 026 Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls

Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M and Madersbacher S
Eur Urol 2005;48 (1),Jul: 34-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/15967249>

CGA 025 Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination

Fracalanza S, Prayer-Galetti T, Pinto F, Navaglia F, Sacco E, Ciaccia M, Plebani M, Pagano F and Basso D
Urol Int 2005;75 (1),57-61.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/16037709>

CGA 024 Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease

Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A and Dogliotti L
Endocr Relat Cancer 2005;12 (1),Mar: 109-17.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/15788643>

CGA 023 Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A

Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D'Eramo G and Silverio FD
Prostate 2004;58 (4),Mar 1: 421-8.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/14968443>

CGA 022 Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma

Sciarra A and Di Silverio F
Urology 2004;63 (3),Mar: 523-7.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/15028450>

CGA 021 Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R and Di Silverio F
Prostate 2003;55 (3),May 15: 168-79.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/12692782>

CGA 020 Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma

Sciarra A, Gentile V, Monti S, Mariotti G, Pastore A and Di Silverio F
Arch Androl 2003;49 (1),Jan-Feb: 39-48.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/12647777>

CGA 019 Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy

Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T and Ito H
Eur Urol 2003;44 (3),Sep: 309-14; discussion 314.(Studies,)

<https://www.ncbi.nlm.nih.gov/pubmed/12932928>

CGA 018 Neuroendocrine serum tumour markers in hormone-resistant prostate cancer

Hvamstad T, Jordal A, Hekmat N, Paus E and Fossa SD
Eur Urol 2003;44 (2),Aug: 215-21.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/12875941>

CGA 017 Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer

Chuang CK, Wu TL, Tsao KC and Liao SK
J Formos Med Assoc 2003;102 (7),Jul: 480-5.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/14517586>

CGA 016 Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients

Tarle M, Ahel MZ and Kovacic K
Anticancer Res 2002;22 (4),Jul-Aug: 2525-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/12174956>

CGA 015 Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer

Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N and Ito H
J Urol 2002;167 (2 Pt 1),Feb: 512-5.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11792908>

CGA 014 Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients

Zaky Ahel M, Kovacic K, Kraljic I and Tarle M
Anticancer Res 2001;21 (2B),Mar-Apr: 1475-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11396235>

CGA 013 Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas

Tsao KC and Wu JT
Clin Chim Acta 2001;313 (1-2),Nov: 21-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11694235>

CGA 012 Serum chromogranin-A in advanced prostate cancer

Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M and Pichon MF
BJU Int 2001;88 (7),Nov: 790-6.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11890255>

CGA 011 Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients

Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D and Angeli A
Prostate 2001;47 (3),May 15: 205-11.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11351350>

CGA 010 Cross-correlation of serum chromogranin A, %F-PSA and bone scans in prostate cancer diagnosis

Ahel MZ, Kovacic K and Tarle M
Anticancer Res 2001;21 (2B),Mar-Apr: 1363-6.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/11396214>

CGA 009 The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate

Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G and Logothetis C
Urol Oncol 2000;5 (3),Apr 1: 97-103.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10765015>

CGA 008 Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate

Ischia R, Hobisch A, Bauer R, Weiss U, Gasser RW, Horninger W, Bartsch G, Jr., Fuchs D, Bartsch G, Winkler H, Klocker H, Fischer-Colbrie R and Culig Z
J Urol 2000;163 (4),Apr: 1161-4; discussion 1164-5.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10737487>

CGA 007 Circulating neuroendocrine markers in patients with prostate carcinoma

Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi R, Bollito E, Fontana D and Angeli A

Cancer 2000;88 (11),Jun 1: 2590-7.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10861438>

CGA 006 Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases

Wu TL, Chang CP, Tsao KC, Sun CF and Wu JT
J Clin Lab Anal 1999;13 (6),312-9.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10633301>

CGA 005 Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy

Wu JT, Wu TL, Chang CP, Tsao KC and Sun CF
J Clin Lab Anal 1999;13 (6),308-11.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10633300>

CGA 004 Serum chromogranin A in monitoring metastatic prostate cancer patients

Tarle M
Anticancer Res 1999;19 (6C),Nov-Dec: 5663-6.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/10697637>

CGA 003 Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients

Wu JT, Astill ME, Liu GH and Stephenson RA
J Clin Lab Anal 1998;12 (1),20-5.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/9484665>

CGA 002 Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerod OK and Waldum HL
Prostate 1997;30 (1),Jan 1: 1-6.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/9018329>

CGA 001 Elevated plasma chromogranin-A concentrations in prostatic carcinoma

Kadmon D, Thompson TC, Lynch GR and Scardino PT
J Urol 1991;146 (2),Aug: 358-61.(Studies,)
<https://www.ncbi.nlm.nih.gov/pubmed/1856931>

Clinical Diagnostics	Thermo Fisher Scientific B·R·A·H·M·S GmbH Neuendorfstr. 25 16761 Hennigsdorf Germany	+49 (0)3302 883 0 +49 (0)3302 883 100 fax info.brahms@thermofisher.com www.thermoscientific.com/brahms
-----------------------------	--	---

ThermoFisher
S C I E N T I F I C

Not all products are CE marked or have 510(k) clearance for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.

© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.